1. Toxic Activation of an AAA+ Protease by the Antibacterial Drug Cyclomarin A.
- Author
-
Maurer M, Linder D, Franke KB, Jäger J, Taylor G, Gloge F, Gremer S, Le Breton L, Mayer MP, Weber-Ban E, Carroni M, Bukau B, and Mogk A
- Subjects
- ATPases Associated with Diverse Cellular Activities genetics, ATPases Associated with Diverse Cellular Activities metabolism, Anti-Bacterial Agents chemistry, Anti-Bacterial Agents isolation & purification, Escherichia coli cytology, Models, Molecular, Molecular Conformation, Mycobacterium tuberculosis drug effects, Mycobacterium tuberculosis enzymology, Oligopeptides chemistry, Oligopeptides isolation & purification, ATPases Associated with Diverse Cellular Activities antagonists & inhibitors, Anti-Bacterial Agents pharmacology, Escherichia coli chemistry, Oligopeptides pharmacology
- Abstract
ATP-driven bacterial AAA+ proteases have been recognized as drug targets. They possess an AAA+ protein (e.g., ClpC), which threads substrate proteins into an associated peptidase (e.g., ClpP). ATPase activity and substrate selection of AAA+ proteins are regulated by adapter proteins that bind to regulatory domains, such as the N-terminal domain (NTD). The antibacterial peptide Cyclomarin A (CymA) kills Mycobacterium tuberculosis cells by binding to the NTD of ClpC. How CymA affects ClpC function is unknown. Here, we reveal the mechanism of CymA-induced toxicity. We engineered a CymA-sensitized ClpC chimera and show that CymA activates ATPase and proteolytic activities. CymA mimics adapter binding and enables autonomous protein degradation by ClpC/ClpP with relaxed substrate selectivity. We reconstitute CymA toxicity in E. coli cells expressing engineered ClpC and ClpP, demonstrating that gain of uncontrolled proteolytic activity causes cell death. This validates drug-induced overriding of AAA+ protease activity control as effective antibacterial strategy., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF